Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
Phase 3 Program Underway to Further Assess Brodalumab as Potential Treatment for People Living With Psoriatic Arthritis THOUSAND OAKS, Calif. and LONDON, June 11, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal […]